RxDoctor Payments DataLook up a doctor →

Robin Dailey

Nurse Practitioner · Marion, ILNPI 1265893051

Payments from drug & device makers

$13,510in general payments, 2019–2025

Across 835 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • GSK$867
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$13,510100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,510 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$56,787
Medicare patients
247
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$141,201
JardianceEmpagliflozin102$116,551
TrulicityDulaglutide62$80,011
FarxigaDapagliflozin Propanediol71$76,290
MounjaroTirzepatide41$57,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$52,882
EliquisApixaban43$46,718
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$30,675
VascepaIcosapent Ethyl38$27,399
LinzessLinaclotide28$22,251
RybelsusSemaglutide11$19,423
JanuviaSitagliptin Phosphate18$17,311
Repatha SureclickEvolocumab14$16,674
TradjentaLinagliptin18$13,294
MyrbetriqMirabegron13$10,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,242$160,623108 claims
Lilly USA, LLCTrulicity, Mounjaro$1,422$137,052103 claims
Boehringer IngelheimJardiance, Tradjenta$602$129,846120 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,722$106,965113 claims
GSKTrelegy Ellipta, Breo Ellipta$867$61,32260 claims
PfizerEliquis, Prempro$1,042$49,92657 claims
AbbVieLinzess, Synthroid$2,448$23,64753 claims
MerckJanuvia$172$17,31118 claims
Astellas Pharma US IncMyrbetriq$130$10,75913 claims
Johnson & JohnsonXarelto$54$8,83313 claims
BayerKerendia$308$7,70512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Marion

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →